All-oral Combination of Daclatasvir Plus Asunaprevir in Interferon Ineligible Naive/Intolerant and Nonresponder
Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Phase 3 Trial
By simply tweaking the number of receptors down, we were able to transform a nonresponder
into a responder," said Prof Hen, whose research is reported in the journal Neuron.
group included 1 pneumonectomy, 12 lobectomies, 5 wedge resections, 3 lung biopsies, 1 lymph node biopsy with metastatic disease, and 1 cytology cellblock from a lung fine-needle aspiration biopsy.
This assay may be useful as a tool in deciding whether a nonresponder
should increase the dose of clopidogrel (pharmacokinetic type of resistance) or change to a different antiplatelet drug (pharmacodynamic type of resistance).
The control classrooms did not participate in the nonresponder
portion of the study.
Your cholesterol might not budge, but that wouldn't mean you're a nonresponder
The Emerging Markets Physician & Payer Forum report entitled Positioning of Current and Emerging Agents for Hepatitis C Virus: Physician and Payer Perspectives on the Prescribing and Patient Access Landscape in Brazil, Mexico, and Argentina also finds that peg-IFN-alpha (Roche's Pegasys and Merck's PegIntron) enjoys full government sponsorship in all three countries, but current access to protease inhibitors (Johnson & Johnson's Incivo and Merck's Victrelis) is still very limited in some of the markets; therefore, peg-IFN/ribavirin is the treatment that surveyed clinicians most frequently prescribe to treatment-naive and nonresponder
By 1 year follow-up, the nonresponder
rate had fallen to 21%.
The primary objective of the ongoing Phase II study is to determine the safe and effective dose range of SCH 503034 in combination with PEG-INTRON in the HCV genotype 1 nonresponder
For the nonresponder
analysis, a sample of 1,241 physicians (14.
Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that the Data Safety Monitoring Board (DSMB) responsible for reviewing its Phase 2 trial of Ceplene (histamine dihydrochloride) for the treatment of hepatitis C nonresponder
patients has concluded that there have been no safety concerns associated with the triple-drug combination of Ceplene, Peg-Intron(R) (peginterferon alfa-2b) and Rebetol(R) (ribavirin, USP).
The results with the combination of 400 mg of valopicitabine and pegylated interferon were less promising in the nonresponder
study population, with about a 2.